The CLL Sessions: highlights from EHA and ICML 2021
VJHemOnc Podcast
Comparing the Efficacy and Side Effects of Akylobrutinib and Britinib in CLL Patients
This chapter discusses two different studies comparing the efficacy and adverse events of a second-generation VTK inhibitor, akylobrutinib, with a britinib in high-risk patients with CLL. The first study focuses on the non-inferiority of akylobrutinib compared to a britinib in terms of progression-free survival, while the second study examines the occurrence of atrial fibrillation and other adverse events. The analysis suggests that akylobrutinib has a lower rate of cardiovascular adverse events, particularly atrial fibrillation, compared to a britinib.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
